Saturday, October 31, 2026

European Insurers Resist Private Credit While North American Rivals Double Exposure

European and North American insurers are diverging sharply on private credit investments. Axa and Allianz are holding back on expansion while U.S. firms like North American Company for Life and Health Insurance deepen alternative asset partnerships to boost yields. The split reflects different regulatory frameworks, with Europe's Solvency II rules penalizing illiquid assets.

LM Salvado
LM Salvado

March 16, 2026

Source Trace Score10 source documents10 with a live linkVerifiability: High
European Insurers Resist Private Credit While North American Rivals Double Exposure
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

European insurers Axa and Allianz are resisting private credit expansion while North American rivals increase allocations to alternative assets. The divide reflects competing regulatory pressures across the Atlantic.

Axa CEO Thomas Buberl said the French insurer's private credit exposure sits "far below" competitors. Allianz chief investment officer Claire-Marie Coste-Lepoutre confirmed the German firm remains "very comfortable" with current positions, signaling no aggressive expansion plans.

North American Company for Life and Health Insurance, one of the largest U.S. fixed index annuity issuers, is moving the opposite direction. The firm launched a growth-focused index option for its Secure Horizon FIA products. Executive Tom Haines said the index "has low correlation to the other indices in the portfolio," adding diversification.

Europe's Solvency II capital rules impose higher charges on illiquid assets, making private credit less attractive from a regulatory capital perspective. North American insurers face different constraints—pressure to generate higher yields on general account portfolios to meet fixed index annuity guarantees.

Private credit typically offers 200-400 basis points above comparable public bonds. For North American insurers promising minimum guaranteed returns plus market-linked upside, that yield premium justifies liquidity risk and the need for sophisticated credit analysis.

The divergence also reflects different views on market timing. European insurers may be waiting for better entry points as private credit markets mature and pricing becomes more transparent. North American firms appear willing to accept current valuations for immediate yield enhancement.

Both sides are using reinsurance transactions and strategic divestitures to manage risk as they adjust alternative asset allocations. These moves maintain balance sheet flexibility while pursuing higher-yielding investments in private markets.

Source documents

Via News is a conduit. We point to the source documents behind this report — we don't replace them. Trace any claim to its source and decide what to trust. How we source

Source Trace Score10 source documents10 with a live linkVerifiability: High
  1. [1]News articleYahoo Finance· December 23, 2025
    North American® and Annexus launch new Index with Deutsche Bank and ICE Data Indices for the Secure Horizon Fixed Index Annuity suite
  2. [2]News articleYahoo Finance· February 26, 2026
    Private credit’s great divide: Imminent crisis or ‘no big deal’
  3. [3]News articleYahoo Finance· February 10, 2026
    539 Merrill Advisors Recognized on Forbes' Top Women Wealth Advisor Lists
  4. [4]Press releaseGlobeNewswire· February 3, 2026
    Brandon Hall Group Prepared to Host 2026 HCM Excellence Conference Next Week
  5. [5]Earnings callYahoo Finance· February 13, 2026
    Credicorp Q4 Earnings Call Highlights
  6. [6]Press releaseGlobeNewswire· February 4, 2026
    Europe and North America Home and Small Business Security System Market Report 2026: DIY Convergence, AI Integration, and Smart Home Competition Reshape the Landscape - Forecast to 2031
  7. [7]News articleSeeking Alpha· February 20, 2026
    F&G signals shift toward 25% fee-based earnings by 2028 while expanding AUM and capital flexibility
  8. [8]Press releaseGlobeNewswire· February 3, 2026
    Quantum Computing Market to Grow at Over 30% CAGR Through 2031 Driven by Government Funding, Enterprise Adoption, and Advances in High-Performance Computing | Astute Analytica
  9. [9]News articleYahoo Finance· February 24, 2026
    TBC Bank Group Investor Day: Targets 15%+ Loan Growth, 23%+ ROE and Teases Uzbekistan IPO Option
  10. [10]News articleYahoo Finance· February 11, 2026
    TPG Calls 2025 a “Breakout Year” at BofA Conference, Targets Another $50B+ Fundraising Year

In this story · Knowledge Files

LM Salvado
LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com